Compare · CTNM vs JNJ
CTNM vs JNJ
Side-by-side comparison of Contineum Therapeutics Inc. (CTNM) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTNM and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $609.12B, about 1144.9x CTNM ($532.0M).
- Over the past year, CTNM is up 233.9% and JNJ is up 54.6% - CTNM leads by 179.3 points.
- CTNM has been more active in the news (16 items in the past 4 weeks vs 10 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 5 for CTNM).
- Company
- Contineum Therapeutics Inc.
- Johnson & Johnson
- Price
- $14.29+2.36%
- $253.01+1.39%
- Market cap
- $532.0M
- $609.12B
- 1M return
- +14.92%
- +7.55%
- 1Y return
- +233.88%
- +54.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 16
- 10
- Recent ratings
- 5
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest CTNM
- Amendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.
- Contineum Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Scientific Officer Lorrain Daniel S. exercised 1,040 shares at a strike of $1.01 and sold $16,640 worth of shares (1,040 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)
- CEO and President Stengone Carmine N. exercised 2,500 shares at a strike of $1.01 and sold $40,000 worth of shares (2,500 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Lorrain Daniel S. exercised 33,009 shares at a strike of $1.01 and sold $594,578 worth of shares (37,179 units at $15.99) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 135,202 units (SEC Form 4)
- CMO & Head of Development Watkins Tim exercised 10,833 shares at a strike of $4.50 and sold $173,590 worth of shares (10,833 units at $16.02) as part of a pre-agreed trading plan (SEC Form 4)
- CEO and President Stengone Carmine N. exercised 10,000 shares at a strike of $1.07 and sold $160,080 worth of shares (10,000 units at $16.01) as part of a pre-agreed trading plan (SEC Form 4)
- Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
- SEC Form 4 filed by Director Miralles Gines Diego
- SEC Form 4 filed by Director Lyons-Williams Lori
Latest JNJ
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson